State Secretary at HMWEVW Dr. Philipp Nimmermann visits BioSpring in Frankfurt-Fechenheim
Frankfurt-Fechenheim, March 2023 Dr. Philipp Nimmermann, State Secretary in the Hessian Ministry of Economic Affairs, Energy, Transport and Housing (HMWEVW), visited the production site of BioSpring GmbH in Frankfurt-Fechenheim on Friday, March 3, 2023. BioSpring is a leading global manufacturer of active pharmaceutical ingredients based on synthetic nucleic acids and announced last year an expansion to 40,000 square meters in the city of Offenbach.
During the meeting, the two managing directors and owners Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün highlighted the importance of BioSpring's production of therapeutic nucleic acids to provide a new class of treatment options for a wide range of untreatable diseases, or diseases lacking effective treatment options through conventional pharmaceuticals. These include neurological disorders, metabolic diseases, and types of cancer. In addition to these therapeutic applications, the so-called "oligonucleotides" are also already being used successfully in diagnostics and research and development. BioSpring provides clinical and commercial stage manufacturing and analysis of therapeutic oligonucleotides for pharmaceutical and biotech companies worldwide. BioSpring is also the global market leader for the production of gRNA, the main component of the so-called "gene scissor" (CRISPR/Cas), which is used in cell and gene therapy.
During a tour of the complex clean room production facilities and analytical laboratories, Dr. Nimmermann gained insight into the high-quality standards that clinical and commercial therapeutic production requires.
"We are very pleased about the visit by State Secretary Dr. Nimmermann and the interest in the topic of high-tech active pharmaceutical ingredient production," said Managing Director Dr. Sylvia Wojczewski.
"To be a successful business location, it is imperative to have innovative companies like BioSpring," expressed Dr. Nimmermann.
About BioSpring:
BioSpring is a contract manufacturer for the biotech and pharmaceutical industry and a global leader in production and analysis of so-called oligonucleotides, which are used in clinical and commercial therapies, research, and diagnostics. Oligonucleotides are composed of the same building blocks as human genetic material. BioSpring is the world's leading manufacturer of the main component of the therapeutic "gene scissor" which is used in cell and gene therapy. The active pharmaceutical ingredients produced at BioSpring have powerful implications to the future of treating a wide range of untreatable diseases. These include novel compounds for the treatment of cardiovascular, neurological, and metabolic diseases, as well as various cancers. BioSpring was founded in Frankfurt am Main by Dr. Hüseyin Aygün and Dr. Sylvia Wojczewski, who were then doctoral students at Goethe University, and is still owner-managed. The company, which now has almost 500 employees, has its production headquarters in Frankfurt-Fechenheim and a subsidiary in San Diego, USA.
From left to right: Dr. Sylvia Wojczewski, Dr. Philipp Nimmermann, Dr. Hüseyin Aygün
Photo: Die Profifotografen (Lina Prehn).
Contact
Dr. Martin Schink, Senior Team Lead Marketing
BioSpring Gesellschaft für Biotechnologie mbH
Alt-Fechenheim 34, 60386 Frankfurt am Main
Telefon: +49 (0) 69 66055000
E-Mail: